January 2, 2014 Buy to open the PowerShares DB Base Metals ETF (DBB) on margin. The global economy enters 2014 with mounting momentum. That’s bullish for base metals, copper in particular. To capitalize, we’re adding a leveraged position on the PowerShares DB Base Metals ETF (DBB), which owns equal… Read More
Our seasoned team of analysts continually monitors investment opportunities around the world, to provide investors with the widest possible array of money-making ideas.
Analyst Articles
Sell to close the Gilead Sciences (GILD) May 72.50 call option, at the market. Stocks are under a bit of pressure this morning and our indicators suggest the market will have to digest even more selling in the near term. We therefore want to lock in our healthy gain… Read More
Stocks are set to close out the year on an up note, a theme that has been echoed repeatedly throughout 2013 with shares up 32 percent on the S&P 500. There’s good reason to celebrate, with the economy improving, plenty of slack to absorb even faster growth and consumer confidence… Read More
We have a nice profit on our Gilead Sciences (GILD) May 72.50 call option. The stock has paused in the $75 area after rebounding, but we expect further gains in the next few weeks. Hold on to your position. Gold is once more probing its former lows in very light… Read More
We are selling one third of our Idenix Pharmaceuticals (IDIX) position. IDIX will now be approximately 8 percent of our portfolio. On December 18, we took an aggressive stance and purchased additional shares of Idenix Pharmaceuticals (IDIX). The move has paid off as the stock rallied… Read More
Markets are on track for a record year, given the signs of economic strength and ultra-easy monetary policies of world central banks. If the world indeed stands en route to recovery, we might be in for another good year in 2014—especially when it comes to commodities. We… Read More
The Fed has started tapering, and, contrary to many expectations, the markets jumped on the news. Stocks rallied on the day of the announcement, and continued to perform well, with the major indices standing, once again, in record territory, at the close on Monday. That can be… Read More
Sell to close the Nike (NKE) January 72.50 put option, at the market. Also sell to close the Carnival Corp. (CCL) January 32 put option, at the market. The race (waiting game) for overvalued Nike (NKE) to pullback is turning into a marathon. Unfortunately, the option we purchased was suitable… Read More
The big news this week, of course, is that beginning in January, the U.S. Federal Reserve will finally start to taper, or reduce the size of, its bond-purchase program. Although the stream of good economic data lately and a rare budget accord in Washington had increased the chances of taper,… Read More
We are buying an approximate 6 percent stake in Carter’s Inc. (CRI) and we are increasing our position in Idenix Pharmaceuticals (IDIX) to approximately 10 percent. We are selling Vivus (VVUS) and St. Joe Corporation (JOE). After working for famed investor Julian Robertson’s Tiger Management, Chase Coleman, III, founded… Read More